Michael Eaddy, PharmD, PhD
Articles by Michael Eaddy, PharmD, PhD
Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMIT
ByRichard H. Stanford, PharmD, MS,Anna D. Coutinho, PhD,Michael Eaddy, PharmD, PhD,Binglin Yue, MS,Michael Bogart, PharmD This cost analysis using data from the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial found that fluticasone furoate/vilanterol reduced the rates and costs of combined chronic obstructive pulmonary disease (COPD) exacerbations and revascularization/cardiovascular events versus placebo.
Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics
ByLucio Gordan, MD,Marlo Blazer, PharmD, BCOP,Vishal Saundankar, MS,Denise Kazzaz,Susan Weidner, MS,Michael Eaddy, PharmD, PhD Administration of immuno-oncology therapy for cancer diagnoses in the community clinic setting is associated with lower costs compared with administration in a hospital-based clinic setting.